Annual Report
Released
Released
Announcement PDF
ANNUAL R EPOR T 2023
The
Microbiome
Health
Company
Biome aims to improve the health
and quality of life of Australians
suffering from some of the most
common and chronic health
conditions using evidence-based
complementary medicines.
As a microbiome health company that pursues clinical trials, Biome works
at the intersection of the natural medicine and pharmaceutical world. Biome
Australia develops, licenses, commercialises, and markets innovative,
evidence-based live biotherapeutics (probiotics) and complementary
medicines, many of which are supported by clinical research.
In partnership with some of the world’s leading organisations in
microbiome research and development, Biome produced several
unique live biotherapeutic (probiotic) products with innovative delivery
technologies that improve their stability and efficacy to create its
flagship range of complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised, double-blind,
placebo-controlled trials, Activated Probiotics® help prevent and support
the management of various health concerns, including low mood and
sleep, bone density loss, iron malabsorption, mild eczema and irritable
bowel syndrome (IBS). Through practitioner-only distribution, Biome
is committed to educating health professionals on the newfound
systemic health effects of the gut microbiota, helping them to provide
innovative, evidence-based natural medicines for the management of
some of humanity’s most prevalent and chronic health concerns.
Acknowledgement of Country
We acknowledge the Wurundjeri people as the Traditional Owners
on whose Country we are based. We pay respect to their Elders past,
present and emerging and acknowledge their continuing connection
to land, sea and community. We extend that respect to Traditional
Owners throughout Australia where we work and operate.
2
Biome | The Microbiome Health Company
Introduction
Company timeline
Probiotics 101
Our offering
Chair letter to shareholders
CEO letter to shareholders
Operations Report
Targeted products for targeted outcomes
Innovating with new targeted products in FY24
Culture & Values
B Corp
People & recruitment
Sales & Education
Education & training
Sales
Key customers and distribution channels
Building our Brand
Pharmacy channel marketing
Health clinics
Practitioner channel marketing
Growth strategies
International market summary
Annual Financial Statements
02
04
06
10
12
14
16
18
18
22
24
24
26
28
30
32
34
36
36
38
40
40
42
3
Company timeline
20
18
20
19
JULY
JANUARY
MARCH
Biome Australia
Founded
Activated
Nutrients® Launch
MARCH
6 employees
Biome launches its
certified organic range
of nutraceuticals
Biome gains distribution
with pharmaceutical
wholesaler Symbion
On the Australian Register
of Therapeutic Goods
SEPTEMBER
JULY
JUNE
MARCH
Activated Probiotics®
increases distribution in
the Australian practitioner
market with Rener Health
Products and Ariya Health
Biome signs strategic
distribution partnership
with TerryWhite
Chemmart including
exclusive national
promotional program
NOVEMBER
NOVEMBER
JUNE
Biome Completes
Initial Public
Offering
3000 Distribution
Points
JUNE
JULY
JULY
JUNE
Rener &
Ariya Health
Distribution Deal
B Corporation
Certification
Strategic
Distribution
Partnership
Activated
Probiotics®
Product Range
Extensions
At Priceline Pharmacy &
TerryWhite Chemmart
4
Symbion
Distribution Deal
$2.32M FY21
Sales Revenue
Listing of 10
Medicines
Biome Lift™
Clinical Trial
In partnership with La
Trobe University and
Probiotical S.p.A.
20
22
$7.23m FY23 Sales
$4.12m FY22
Sales Revenue
Total of 17 Listed
Medicines on
the ARTG
Biome | The Microbiome Health Company
20
20
JUNE
NOVEMBER
Biome gains distribution
with pharmaceutical
wholesaler API
$387k FY19 sales
revenue
Biome launches its
condition-specific
probiotic range
MARCH
FEBRUARY
FEBRUARY
JANUARY
Biome Daily Kids™
clinical trial commences
in partnership with
Federation University
Activated Probiotics®
launches into the
Australian practitioner
market with Oborne
Health Supplies
and vital.ly
Probone21 clinical
trial using Biome
Osteo™ commences in
partnership with La Trobe
University and Probi AB
JUNE
JUNE
SEPTEMBER
API Distribution
Deal
2000
Distribution
Points
JUNE
Priceline Pharmacy
Distribution Deal
Activated
Probiotics® Launch
Biome Daily Kids™
Clinical Trial
30 Employees
Biome signs distribution
deal with Priceline
Pharmacy
JUNE
TerryWhite
Chemmart
Distribution Deal
Activated Probiotics®
launches nationally with
TerryWhite Chemmart
$833k FY20 sales
revenue
Practitioner
Market Launch
Total of 14 Listed
Medicines on
the ARTG
NOVEMBER
UK Practitioner
Market Launch
Activated Probiotics®
launches into the UK
Practitioner market
20
21
Biome Osteo™
Clinical Trial
Priceline Pharmacy
Activated
Probiotics®
Product Launch
20
23
JUNE
Biome Lift™
Clinical Trial
Final Results
MAY
MARCH
Biome Recruits
Health Retail
Sales Manager
for the UK
Biome Lift™
Clinical Trial
Preliminary
Results
For future pharmacy
and health food launch
On patients with sub
threshold depression
OCTOBER
Inaugural AP
Symposium
‘Women In The
New World’
5
Probiotics 101
“The gut microbiome can
impact many aspects of
human health, and how
the health benefits of
probiotics can go far beyond
the digestive system.”
Probiotics 101
Probiotics are living microorganisms that have been found
to be beneficial to health when taken as a supplement.
Targeted probiotic actions
In the gut, probiotics that we take and the microorganisms
that live there are alive with activity and interact with
all kinds of cells in the digestive tract—including cells
that are part of our immune system, hormone-secreting
cells, nerve cells and more. They also turn our food
into energy and produce bioactive compounds called
metabolites in the process. We can absorb these
metabolites just like nutrients, which then travel
through circulation to other parts of the body.
This is because different probiotic strains, even within
the same species, perform very different biological
functions in the human gastrointestinal tract and, as
a result, offer vastly different health benefits.
These actions are how the gut microbiome can impact
many aspects of human health, and how the health benefits
of probiotics can go far beyond the digestive system.
This is the key to targeting specific health concerns with
probiotic supplements, and why it’s so important to know
exactly which strains are present in a probiotic product.
It is well-established that probiotics can improve digestion
and the health of our gastrointestinal tract, but the links
between the digestive tract and the rest of the body
allow probiotics to impact the health of our whole body.
6
Not all probiotic microorganisms offer
the same health benefits.
7
The gut microbiome
The gut
microbiome
Demonstrating the
proposed links between an
unhealthy gut microbiome,
inflammation and increased
risk of chronic disease.
Scientific research has helped to reveal an additional
organ system that has been invisible to the naked eye
for much of human history: the gut microbiome. Just like
we need lungs to breathe and a heart to pump blood
around our bodies, we now know that the community
of microorganisms living in our gut operates like a
vital organ and is just as crucial for our health.
When the gut microbiome is healthy, the whole body
benefits. However, just like any other organ, the gut
microbiome can become disrupted and negatively impact
our health. This is referred to as ‘gut dysbiosis’ and it has
now been associated with many chronic diseases, including
irritable bowel syndrome, depression, asthma, acne,
osteoporosis and countless others.
Disruptions to the makeup of the gut microbiome is thought
to negatively impact health through a number of different
mechanisms. For example, an unhealthy gut microbiome
triggers a breakdown of intestinal cell health and a
phenomenon known as leaky gut which allows for the gut
microbiome to interact with the underlying immune system.
The immune system’s response to potentially harmful
microbes from an unhealthy gut can create inflammation
which travels from the gut to the rest of the body via
8
chemical messengers (e.g. cytokines) circulating in the
blood. Chronically raised inflammation stemming from the
gut is thought to impact the health of many different organ
systems, and contribute to the increasing prevalence of
chronic disease.
The rise in gut dysbiosis (and its negative health effects) is
thought to be due to several factors. Changing diets with
lower intakes of fibre and unrefined plant foods, stressful
lifestyles, low activity levels and increased use of antibiotics
—these factors reduce the population and change the types
of microorganisms found in the gut, creating gut dysbiosis.
Fortunately, probiotics have emerged as a way to intervene.
Beneficial probiotic bacteria represent a new generation
of therapeutic agents which may be able to mitigate
the negative effects of an unhealthy gut microbiome on
different aspects of human health. In human clinical trials,
specific strains of beneficial probiotic bacteria have now
been shown to improve health outcomes in a number of
chronic diseases.
1. Anwar, H., Irfan, S., Hussain, G., Naeem Faisal, M., Muzaffar, H., Mustafa, I.,
Mukhtar, I., Malik, S., & Irfan Ullah, M. (2020). Gut Microbiome: A New Organ
System in Body. In Parasitology and Microbiology Research (pp. 1–20). IntechOpen
Biome | The Microbiome Health Company
DIETARY FIBRES
TARGETED
PROBIOTICS
REDUCED RISK OF
CHRONIC DISEASE
ANTIBIOTICS
WESTERN DIET +
LIFESTYLE
9
Our offering
17
Activated Probiotics® currently
has 17 products in its portfolio
across three brands which
continue to grow as new
products are developed.
Clinically trialled
Practitioner-only
Elevating the credibility of Biome’s products through working with
health professionals to support their active recommendation of
Biome’s products.
Biome Australia’s live
biotherapeutic products
are all supported by clinical
evidence of efficacy. Six live
biotherapeutic products
are supported by human
clinical trials on the finished
formulations, in many cases
first in the world.
20,000+ Three
health professionals educated throughout
FY23 by Biome’s education team.
Expertise
The board and management has a strong global track record with
existing professional networks across the healthcare industry in
Australia, Asia and Europe. The expertise and passion of Biome’s team
sets Biome apart and is a critical and unique differentiator.
10
ongoing clinical trials
• Biome Lift™ and subthreshold
depression
• Biome Osteo™ and osteopenia
• Biome Daily Kids™ and
children’s immune health
Biome | The Microbiome Health Company
Condition specific
Activated Probiotics® has
produced a range of conditionspecific live biotherapeutic
probiotic products that may
help to prevent osteoporosis,
reduce the severity and
frequency of asthma attacks,
reduce depressive symptoms
and increase iron absorption.
Nine
proprietary products
The product portfolio includes 9
proprietary Activated Probiotics®
products (live biotherapeutic
probiotics and nutraceutical
products) to which Biome owns
the formulation.
Probiotics as live
biotherapeutic
products
Biome denotes probiotic bacteria that target
specific therapeutic outcomes in disease
states as ‘live biotherapeutics.’
This term has been adopted by the company to differentiate
probiotic strains with general health benefits often used
in fast-moving consumer goods and food supplements,
and those that have clinical evidence supporting their
therapeutic application in specific health conditions.
Due to the increasing body of evidence supporting the
therapeutic application of specific probiotic strains in
disease states, live biotherapeutics are increasingly
regarded as their own class of therapeutic goods.
The U.S. Food and Drug Administration defines a live
biotherapeutic product as a biological product that
contains live organisms, such as bacteria, is applicable
to the prevention, treatment or cure of a disease or
condition of human beings, and is not a vaccine.
Biome’s Activated Probiotics® range is more aligned
with the principles of live biotherapeutic products.
Each Biome product has been carefully formulated
with specific clinically-trialled probiotic strains at doses
known to target a particular health concern, creating
a range of condition-specific probiotics products.
Biome has products that target immune health,
irritable bowel syndrome, infant colic, bone
density, eczema, acne, muscle inflammation,
mood and sleep, vaginal health, and more.
11
Chair letter to shareholders
12
Biome | The Microbiome Health Company
Chair letter to
shareholders
Dear fellow shareholders,
It gives me great pleasure to present Biome
Australia’s FY23 Annual Report.
FY23 is another impressive year of results for the
Biome team as they continue to execute on our
strategy. Biome products are available through multiple
distribution points around Australia via community
pharmacy, independent health practitioners and
through health professionals in the United Kingdom.
Locally, Biome’s national pharmacy distribution has
been strengthened through our key partnerships with
TerryWhite Chemmart and Priceline Pharmacy.
Our team has delivered
another year of strong
growth, reaching sales of
$7.23m, up 75% on FY22.
The substantial growth in
FY23 has enabled Biome to
begin FY24 with a forecasted
Q1 revenue of $2.5M.
I am once again very pleased with the financial performance
of Biome, delivering substantial revenue growth, reduced
operating losses and gross margin maintained.
Our UK business has developed sustainable revenue
in FY23, with minimal resources, helping develop
a fantastic platform to execute their FY24 growth
strategy. We have recently recruited additional sales
staff to drive the UK and EU markets which will
include health retail channel launches in FY24.
When I joined Biome in 2020, the company’s total revenue
was at a similar level to that of our UK business, which will
have the advantage of our proven education driven sales
model to support growth in the territory over the coming
years. The UK market presents a different set of challenges
to our local Australian market, however the sheer size of
the opportunity, and well established health retail and
practitioner markets offer an exciting proposition for Biome.
Having spent the past years cautiously testing the market,
we believe now is the time to apply additional resources
and focus to drive the UK and EU market to their potential.
I appreciate shareholders are eager to know when we
expect to become cash flow positive, while we have
detailed internal modeling, we want to be absolutely
certain before we forecast that to market. Reaching
profitability is a key focus on the Biome Australia Board
to support the long term sustainability of the company.
On behalf of the Biome Board of Directors, I would
like to thank you for your ongoing support.
Ilario Faenza MAICD
Independent Non-executive Chairman
13
CEO letter to shareholders
CEO letter to
shareholders
It is my pleasure to share
this CEO letter: our second
since listing on the ASX.
Biome is one of the first global movers in the targeted
probiotic or live biotherapeutic space. As Founder and
Managing Director, I have had the pleasure of both leading
and watching the company’s growth through initial
conception, the 2019 launch of novel live biotherapeutics
range Activated Probiotics® and listing on the ASX in 2021.
During that time, and to a certain degree at present, the
company has navigated the COVID-19 environment while
delivering on a number of critical operational milestones.
As a company led by our research and development
efforts into new and innovative areas within the global
probiotic marketplace, we are proud to have brought
several novel clinically proven probiotic concepts through
to commercialisation, market acceptance and growth. In
partnership with both community pharmacy and leading
independent health practitioners, Biome and our brand
Activated Probiotics® has cemented itself as one of the
14
most trusted complementary medicine brands in Australia
within a relatively short period of time. Staying true to our
values of honesty, integrity, accessibility and trust, we
work closely with health professionals to support improved
patient health outcomes and produce new solutions for
those who have exhausted other existing therapies.
Throughout the 2023 financial year, Biome successfully
grew its top-line revenue by 75%, successfully launched
further national health retail distribution with Wesfarmers
owned Priceline Pharmacy and completed a world first
clinical trial on patients with subthreshold depression
with our product Biome Lift™ Probiotic. Through a
year where a significant portion of the complementary
medicine market was challenged with major out
of stock issues, Biome was able to navigate these
global supply risks, keeping lines in stock and rapidly
securing market share in the high value community
pharmacy and practitioner distribution channels.
In October 2022, Biome hosted its inaugural education
symposium, Women in the New World, which brought
together a number of key opinion leaders on the topics
and the celebration of women’s health, business, sport
and research. The ticketed event provided a wonderful
platform for Biome to share its industry leading
knowledge on both probiotics and women’s health to an
audience of 200 of our highest value industry partners
and customers over three days in Hobart, Tasmania.
Throughout the year, Biome’s education team also ran a
national Probiotics Masterclass tour, a series of professional
seminars to our practitioner customers. The Masterclass
and Symposium we believe have positioned Biome, within
the eyes of health professions, as a key trusted thought
leader in the probiotic and live-biotherapeutic space.
Biome | The Microbiome Health Company
Further to our strong top line sales results, we also
achieved strong growth in our underlying community
pharmacy business, with a 27% increase in samestore-sales between quarter three and quarter four
FY23 and for the full financial year Biome maintained
a gross margin of 59%, an increase on FY22.
As Biome continues to grow, it has been a key focus of
management to ensure our culture and values remain in
place to support staff retention and recruitment of industry
leading talent. I am proud to share that we have added six
new positions and team members throughout FY23, all
with new skills and relationships to support our growth in
FY24 and beyond. One of these recruits will be leading our
international sales efforts. Tej, our recently recruited UK
health retail sales manager will be leading our launch into
both health food and community pharmacy, our first push
into international retail distribution. This decision was based
on a two-year test market in the UK and the early market
development of a $500k annual revenue business unit that
is supported by a well-established base of customers and
professional relationships. Biome believes the completed
test market period will significantly de-risk our health retail
market launch. Tej brings with him 20 years of probiotic
sales experience in health retail and has led efforts of one
of the largest UK based probiotic brands from its early
days to a £20m annual turnover business in the UK.
To support the UK team, Biome will be working to
secure new health food and pharmacy distributors
in FY24, to add to our portfolio of existing
practitioner distributions in the market.
In our local Australian market, Biome’s Activated Probiotics®
has now secured more than 4000 distribution points
between health retail and independent health practitioners.
To support this growth in distribution, Biome has increased
its stock holding to circa $3m, at cost, at the close of
FY23 and secured access to a debt facility to support
our rolling inventory needs as we continue to grow.
business materially as they are co-funded or completely
funded by Biome’s research and development partners.
As our Activated Probiotics® brand continues to grow
and we work to achieve our goal of being the number one
trusted probiotic brand by health professionals, we turn
our attention to consumer education and knowledge of
our brand. In March 2023, we launched our first public
health campaign. Led by a television commercial aired
on streaming platforms and social media, Biome shared
its Probiotics 101 educational message and introduced
the concept of condition and strain specific probiotics
to the consumer market. These efforts will be ongoing in
FY24 and the goal is to support our distribution channels
with additional foot traffic in their retail stores and
health clinics with patients asking for our products.
As we commence the rollout of our FY24 strategy, I
am pleased to share that for the month of July 2023
we achieved a new sales revenue record with sales
exceeding $900k for the month. This result further
cemented Biome’s ongoing growth after posting a
record quarter in Q4 FY23 with our first $2m quarter.
I thank you all for your continued support working
toward achieving our mission—to prevent disease,
improve health outcomes and quality of life,
and make our products accessible to all.
I look forward to sharing further operational updates
with shareholders throughout financial year 2024.
Blair Vega Norfolk MAICD
Managing Director
Biome continues its research and development efforts and
at the conclusion of FY23, we have two ongoing clinical
research projects on our existing products already in
the market. A PHD candidate at Federation University is
studying Biome Daily Kids™ in a randomised clinical trial,
examining upper respiratory tract infections in children
within a day care setting. La Trobe University is conducting
a follow up study on our Biome Osteo™ Probiotic after
the initial successful trial completed on the product in
Sweden. Both studies represent exciting opportunities
for Biome and its products to support new patient
groups, while increasing the body of evidence behind our
products. Ongoing research efforts are not costing the
15
Operations
Report
Aiming to be a global leader in premium
evidence-based live biotherapeutic products.
Targeted
products
for targeted
outcomes
18
Biome aims to be a
global leader in premium
evidence-based live
biotherapeutic products.
Biome is changing the probiotic space within the Australian,
New Zealand, UK and EU markets through the release of
live biotherapeutic products which each target a specific
health concern and aim to improve patient health outcomes.
In FY23, Biome Australia prepared two new live
biotherapeutic products to launch into the Activated
Probiotics® range. These products have clinical
evidence to support their effectiveness for patients
struggling with constipation, in Biome Lax™ Probiotic,
and dental health concerns with Biome Dental™
Probiotic. Biome also prepared a relaunch of its AXP®
Recovery Probiotic into the Activated Probiotics®
flagship brand. These new product launches will allow
Biome to support new patient health categories and
new types of health professionals and their patients.
Biome | The Microbiome Health Company
Innovating with new
targeted products in FY24
Biome Dental™
Probiotic
Biome Lax™
Probiotic
Biome Recovery™
Probiotic
To help support dental
health and a healthy oral
microbiome.
To help promote bowel
regularity and reduce
occurrence of bloating.
To help improve muscle
recovery time and reduce mild
muscle inflammation.
Benefits supported by ten published
clinical trials on oral health, including
dental plaque and gum health.
Benefits supported by a
randomised, double-blind,
placebo-controlled trial.
Benefits supported by a randomised,
double-blind, placebo-controlled trial.
In one of the most recent trials,
the effect of Biome Dental™
was compared to placebo and
chlorhexidine mouthwash in 60
healthy children. After 14 days
of intake, the average dental
plaque score and gingival index
(a measure of poor gum health)
were 71% and 73% lower in the
Biome Dental™ group compared to
placebo (p<0.05). Biome Dental™
was also found to be more effective
than chlorhexidine, a commonlyprescribed antimicrobial mouthwash.1
In this study, administration of
Biome Lax™ for 30 days was
found to improve bowel regularity
by 37%, reduce the level of
discomfort associated with bowel
movements by 67%, and improve
bloating by 52%, which were
statistically significant when
compared to placebo (p<0.001). 2
1. Sharma, P., Datta, G., Gandhi, K., & Kumar,
D. (2019). A comparative evaluation of efficacy
of probiotic and chlorhexidine mouth rinses
on gingival health and plaque accumulation
in 6-9 year old children. International Journal
of Applied Dental Sciences, 5(1), 156–162.
2. del Piano, M., Carmagnola, S., Anderloni, A.,
Andorno, S., Ballar̈, M., Balzarini, M., Montino, F.,
Orsello, M., Pagliarulo, M., Sartori, M., Tari, R., Sforza, F.,
& Capurso, L. (2010). The use of probiotics in healthy
volunteers with evacuation disorders and hard stools:
A double-blind, randomised, placebo-controlled study.
Journal of Clinical Gastroenterology, 44, 30–34.
This study found that after 21
days of supplementation, the
probiotic formulation in Biome
Recovery™ Probiotic helped to
reduce mild muscle inflammation,
improve muscle recovery time,
and support physical performance
in back-to-back exercises. 3
3. Jäger, R., Purpura, M., Stone, J. D., Turner, S. M.,
Anzalone, A. J., Eimerbrink, M. J., Pane, M., Amoruso,
A., Rowlands, D. S., & Oliver, J. M. (2016). Probiotic
Streptococcus thermophilus FP4 and Bifidobacterium
breve BR03 supplementation attenuates performance
and range-of-motion decrements following muscle
damaging exercise. Nutrients, 8(10), 1–11.
19
Operations Report
Driven by
clinical evidence
The Biome range includes complete product
formulations and specific probiotic strains which are
backed by a high level of clinical evidence, including
many randomised double-blind placebo-controlled
clinical trials. As part of ongoing efforts to strengthen
the existing body of evidence, collaboration with key
world-leading research partners, including LaTrobe
University, Federation University, Probiotical S.p.A.
and Probi AB, has continued throughout FY23.
Over the past financial year, three Biome probiotic
formulations have been the subject of ongoing
clinical trials that aim to build upon their existing
evidence of efficacy. These trials will help to
extend their current body of evidence, while also
investigating their efficacy in new applications.
These research projects are currently investigating
the application of Biome Lift™ Probiotic for
20
subthreshold depression, Biome Daily Kids™ Probiotic
for absenteeism and immune health in children in
day care, and the probiotic strains within Biome
Osteo™ Probiotic for women with osteopenia.
This past year has been highly significant for the
development of Biome Lift™ Probiotic, with the completion
of the Biome Lift™ Trial and receival of positive prepublication results. These results have reinforced the
positive findings of the two previous studies on this
formulation, and provide additional evidence for the
effectiveness of Biome Lift™ Probiotic in reducing
the severity of depressive symptoms in patients with
subthreshold depression. Improvements observed in
inflammatory, metabolic and stress-related biomarkers
(including serum hs-CRP, glutathione, fasting glucose,
and salivary cortisol) are of particular note and provide
important insights into the mechanisms underlying the
actions of Biome Lift™ on mood and sleep-related outcomes.
Enhancing the
performance of
probiotic products
with innovative
manufacturing
and packaging
Microencapsulation technology
Activated Probiotics® uses an innovative
microencapsulation technology to protect its
probiotic bacteria from the harmful effects
of stomach acid, allowing up to 5x more
probiotic bacteria to survive transit through the
stomach and reach the colon alive, compared
to traditional uncoated probiotics.
Pharmaceutical grade blister packaging
Fast-melt formulations for children
Activated Probiotics® capsules are individually
sealed in pharmaceutical-grade blister packing.
This packaging ensures each serve remains
individually sealed until the moment before
consumption and better protects probiotic bacteria
from the damaging effects of environmental
moisture, oxygen and UV light compared to
alternative forms of packaging, such as bottles.
Activated Probiotics® single-serve sachets in
products intended for children over the age
of 2 contain a fast-melt formula that dissolves
in the mouth without the need for water. With
natural sweeteners and vanilla flavouring, this
combination creates an enjoyable experience for
children taking Activated Probiotics® products.
Flow cytometry enumeration
Activated Probiotics® uses the latest flow cytometry
technology to more accurately count the number
of living and metabolically active bacteria found in
its products, when compared to traditional plate
count measures or colony forming units (CFUs).
Flow cytometry technology analyses bacteria
one-by-one using fluorescent dyes and lasers,
ensuring only viable bacteria are counted in
the final tally of ‘billion live bacteria’ (BLB).
21
Culture
& Values
A business can be a force for good.
Culture & Values
24
Biome | The Microbiome Health Company
B Corp
Biome Australia is proud to be a Certified
B Corporation® since 2021.
Certified B Corporations® (B Corps™) are for-profit
companies that use the power of business to build a
more inclusive and sustainable economy. They meet the
highest verified standards of social and environmental
performance, transparency, and accountability.
The Biome team feels strongly that business can be a
force for good. Biome Australia ai
Share your feedback
Discover